Justin Chakma, Chief Business Officer at ARS Pharmaceuticals, Inc. (SPRY), sold 194,280 shares at $14.13 ($2.7M) on 2024-12-05, disclosed to the SEC on 2024-12-06.
Open-market sale of $2.7M SPRY by Chief Business Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $13.95 | 45,000 | $628K | 22.9% |
| 2 | $14.13 | 49,640 | $701K | 25.6% |
| 3 | $14.13 | 49,640 | $701K | 25.6% |
| 4 | $14.23 | 50,000 | $712K | 25.9% |
| Total | $14.11 avg | 194,280 | $2.7M | 100% |
| Filing → |
| SPRY | SELL | 2024-12-12 | $658K | — | Filing → |
| SPRY | SELL | 2024-12-04 | $1.2M | — | Filing → |
| SPRY | SELL | 2024-11-27 | $2.0M | — | Filing → |